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Purpose of review 
Controlling the HIV epidemic remains a major public health challenge and there is an 
urgent need for novel prevention strategies.  Pre-exposure prophylaxis (PrEP) refers to 
the use of antiretrovirals in HIV-negative people at high risk to prevent infection and 
has the potential to be an important component in the global effort to end the HIV 
epidemic by 2030.  We review the current evidence for the safety and efficacy of PrEP in 




Two further randomized control trials report high efficacy of both daily and 
intermittent PrEP in men who have sex with men (MSM) leading to renewed calls for 
wider availability of PrEP for this group. Oral tenofovir disoproxil/emtricitabine has 
been licensed for PrEP in many countries and is well tolerated, safe and effective. 
 
Summary 
Oral PrEP is safe and effective in reducing the incidence of HIV infection in individuals 
at high risk. Implementation in high income countries is progressing slowly; 
demonstration projects and trials continue in low and middle income countries. 
 




- Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication by people who 
are HIV-negative to prevent them from acquiring HIV 
- Most PrEP trials have used containing a fixed dose combination of tenofovir and 
emtricitabine 
- Tenofovir-based PrEP is highly effective in preventing HIV infection in those who take 
it regularly 
- PrEP implementation is beginning but proceeding slowly in many countries amid fears 
about cost, long-term effectiveness and negative impacts on other STI rates, despite 
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economic analyses which have shown it to be highly cost effective, but sensitive to the 










Controlling the global epidemic of HIV remains a major public health challenge.  HIV 
incidence in some adult populations has been static since 2010, challenging efforts to 
end the epidemic by 2030[1]. Indeed, rates have increased in some regions and certain 
at-risk groups [2, 3] highlighting the urgent need for new prevention strategies.  
Traditional approaches to HIV prevention have focused on behavioural change 
including encouraging the use of male condoms and negotiating safer sex, linked to 
regular HIV testing.   
 
Biomedical interventions with proven efficacy in reducing HIV transmission include 
male circumcision [4, 5] and the use of early antiretroviral therapy (ART) to reduce 
infectivity, so called treatment as prevention (TasP). As a strategy, this relies on a high 
proportion of infected individuals being tested, linked to care and starting ART. Post-
exposure prophylaxis (PEP) refers to short course ART to reduce the risk of HIV 
acquisition following a potential occupational or sexual exposure [6]. Despite the 
absence of robust randomized control trial (RCT) evidence it is widely available, and 
used, by some groups such as men who have sex with men (MSM) in high income 
countries. Yet the incidence in many diverse populations in high and low-income 
countries remains high, so new approaches to prevention are still needed.  
 
Pre-exposure prophylaxis (PrEP) refers to the use of antiretroviral medication by 
people who are HIV-negative, in advance of a potential exposure, to prevent them from 
acquiring HIV [7].  There is now strong evidence that PrEP is safe and effective in 
preventing HIV infection and it is recommended for individuals at substantial risk in a 
number of countries [8**,9,10,11]. However, implementation is proceeding slowly amid 
fears about cost, long-term effectiveness and negative impacts on other STI rates. 
 
Evidence for the effectiveness of PrEP 
 
Most PrEP trials to date have used oral tenofovir disoproxil fumarate (TDF), a 
nucleotide reverse transcriptase inhibitor (NRTI) used for the treatment of HIV and 
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chronic hepatitis B. It is available as a fixed dose combination with another NRTI, 
emtricitabine (FTC), marketed as Truvada®.  Pre-clinical studies established the efficacy 
of PrEP in animal models. Oral TDF-FTC prevented infection after vaginal inoculation 
with HIV-1, in humanized mice [12}.  Trials in macaques also found a protective effect of 
tenofovir against simian HIV (SHIV) infection following rectal or oral exposure [13, 14, 
15]. 
  
Ten RCTs evaluating PrEP in humans have been published since 2010 of which 8 
included oral TDF or TDF-FTC.  In the iPREX study, 2499 men or trans-gender women 
who have sex with men, were assigned to receive daily TDF-FTC or placebo. 36 new HIV 
infections were detected in the treatment group compared to 64 in the placebo, an 
efficacy of 44% [16].  Partners PrEP enrolled 4758 serodifferent heterosexual couples in 
Kenya and Uganda where the HIV-positive partner was not on ART.  HIV-negative 
partners were assigned to receive either TDF-FTC, TDF alone or placebo.  There was a 
67% reduction in HIV incidence in the TDF group and 75% in the TDF-FTC group, 
relative to placebo; in those with detectable TDF in plasma there was an 86% reduction 
[17].  The TDF2 study recruited 1219 sexually active HIV-negative men and women in 
Botswana; daily TDF-FTC PrEP was associated with a reduction of 62.2% in HIV 
acquisition relative to placebo in the modified intention-to-treat analysis [18].  The 
Bangkok TDF study enrolled 2413 injecting drug users randomized to either TDF alone 
or placebo. 33 people acquired HIV in the placebo arm compared to 17 in the TDF arm, a 
reduction of 48.9% [19].  All these studies showed that adherence to the PrEP regimen, 
as evidenced by detectable TDF in plasma, was closely correlated with efficacy.  
 
Two large RCTs failed to demonstrate a protective effect of oral TDF-based PrEP.  FEM-
PrEP assigned 2120 HIV-negative women in Kenya, South Africa and Tanzania to either 
oral TDF-FTC or placebo.  HIV infections occurred in 33 women in the TDF-FTC group 
and in 35 women in the placebo group [20].  VOICE enrolled 5029 women in South 
Africa and participants were assigned equally to TDF alone, TDF-FTC, or placebo.  There 
were 52 HIV seroconversions in those receiving oral TDF, 61 in those receiving TDF-
FTC and 60 in those receiving placebo with no significant difference between the 
treatment group and placebo [21].  In both studies, however, the estimated adherence 
to the study drugs was low; in FEM-PrEP less than 40% of participants had evidence of 
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recent pill use based on plasma tenofovir levels, and in VOICE 58% and 50% of women 
in the TDF and TDF-FTC arms respectively had no detectable plasma tenofovir on any 
quarterly plasma sample. Modelling data from the open label extension of the iPREX 
study suggests that daily TDF-FTC PrEP achieves plasma drug levels greatly in excess of 
the protective threshold and that 2-3 tablets per week may be sufficient [22].  However 
this data is from a cohort in whom anal intercourse is the main risk factor for HIV and 
evidence is lacking on the level of adherence required to protect against vaginal 
exposure.   
 
Recent reports from two RCTs in MSM have added important new evidence to guide 
policy on PrEP. The PROUD trial [23*] addressed the question of whether risk 
compensation, whereby individuals may engage in riskier sexual behaviours when they 
perceive themselves to be protected by PrEP, would negate the efficacy demonstrated in 
double-blind RCTs [24,25].  The trial recruited MSM reporting condomless anal 
intercourse (CLAI) within the previous 90 days, and likely to do so again in the next 90 
days.  Participants were randomized to receive oral TDF-FTC PrEP immediately, or 
defer PrEP for 1 year.  Importantly, the trial was open label so as to capture the net 
effect of efficacy, adherence and any change in sexual behaviour and hence provide 
insights into how effective PrEP might be in routine use.  The enrolment of 544 
participants was intended as a pilot but an unexpectedly high incidence of HIV infection 
in the deferred group prompted the steering committee to advise PrEP be offered to all 
in the deferred group immediately.  HIV infection occurred in 3 participants in the 
immediate group versus 20 in the deferred group, a relative reduction of 86%. 
Continued follow-up was undertaken to gain more evidence on longer-term use.  
 
Evidence from macaque studies had shown intermittent PrEP dosing around the time of 
exposure to be at least as effective as daily prophylaxis [13, 26].  The IPERGAY study 
[27*] examined the efficacy of “event-related” PrEP in MSM reporting CLAI with 2 or 
more partners in the last 6 months.  400 participants were randomized to receive oral 
TDF-FTC or placebo and were instructed to take 2 tablets 2-24 hours before intercourse 
followed by 1 tablet 24 and 48 hours later, or a daily pill until 2 days after the most 
recent exposure in the event of multiple episodes of intercourse.  There were two new 
HIV infections in the TDF-TFC group versus 14 in those taking placebo representing an 
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86% relative reduction, identical to the effect observed in PROUD.  Of the two 
participants in the treatment group who acquired HIV, neither had detectable plasma 
drug levels and each returned most of their pills so were clearly non-adherent.   
 
A recent systematic review of PrEP trials [28**] noted the correlation between 
effectiveness and proportion with detectable drug levels. The two studies which failed 
to find an effect of PrEP were both in women participants leading to speculation that 
lower concentrations of TDF in vaginal versus rectal tissue may contribute to the lower 
efficacy, as well as suggesting that regular dosing may be more important in women 
[20,29].  The reasons for poor adherence in VOICE and FEM-PrEP are likely complex 
and multi-factorial. In FEM-PrEP the majority of participants perceived themselves to 
be at low or no risk of HIV [20]. A placebo-controlled trial design may reduce 
adherence, given that the participant knows it may be a placebo [23, 25]. Event-related 
PrEP may offer potential advantages in reduced pill burden, cost and potential drug 
toxicity.  However, efficacy has been demonstrated in only one trial in MSM and cannot 
necessarily be applied to other risk groups.  Moreover participants in IPERGAY took a 
median of 15 pills per month and the authors emphasise that their results cannot be 
extrapolated to those with less frequent exposure taking a more intermittent regimen 
[27].  Although animal models have suggested that TDF-FTC may be more effective than 
TDF alone [13] a recent trial in a heterosexual population showed no difference [30]; 
further evidence is needed for MSM populations. 
 
Alternatives to oral TDF-containing PrEP 
 
Three RCTs have evaluated the effectiveness of a vaginal gel formulation of tenofovir 
used pericoitally (CAPRISA, FACTS 001) or daily (VOICE).  CAPRISA demonstrated a 
modest reduction in HIV incidence of 39% in the active treatment arm in a trial of 889 
women randomised to receive either tenofovir 1% gel or placebo. This increased to 
54% in a subset of high adherers [31].  Both VOICE [21] and FACTS 001 [32] failed to 
demonstrate efficacy.  Adherence was low in both trials, although a subset analysis in 




Longer-acting modes of drug delivery offer the potential to overcome the adherence 
issues observed with PrEP requiring daily or coital use.  Two studies have reported on a 
sustained release vaginal ring (to be changed monthly) containing dapivirine, a non-
nucleoside reverse transcriptase inhibitor.  MTM-020-ASPIRE [33] demonstrated a 27% 
reduction in HIV acquisition and IMP-027 [34] a 30.7% reduction relative to placebo.  
Again, sub-group analyses demonstrated greater efficacy in those with objective 
evidence of adherence. Phase 1 data for a tenofovir vaginal ring has recently been 
published [35].  It is important to note that vaginal delivery would give no protection 
for receptive anal intercourse.  In the PARTNER study which examined HIV 
transmission between serodifferent couples, 23.8% of HIV-negative heterosexual 
women reported anal sex with their HIV-positive partner [36*].   
 
Other agents for PrEP are being studied.  Tenofovir alafenamide (TAF) is another 
prodrug of tenofovir with reduced potential for renal toxicity [37], also coformulated 
with FTC, and protective against rectal SHIV in macaques [38].  Clinical trials are 
underway to determine equivalent efficacy to TDF, with fewer restrictions and less 
renal monitoring. Maraviroc is an entry inhibitor for which safety and tolerability as 
PrEP have been demonstrated in Phase 2 trials [39].  Long-acting injectable 
antiretrovirals offer the possibility of monthly or even 2 monthly injections and Phase 
2b/3 studies are planned [40,41]. 
 
Safety of oral TDF-containing PrEP 
 
TDF and TDF-FTC have been used for the long-term treatment of HIV for almost two 
decades and are safe and well tolerated.  Rates of adverse events in controlled PrEP 
trials were similar in active and controls [28**].  
 
TDF may cause proximal renal tubulopathy in a small proportion of patients [42].   
Small sub-clinical reductions in renal function were noted in i-PREX and the Bangkok-
TDF study which were reversible on stopping PrEP. [43, 44]. However most studies 
excluded patients with a creatinine clearance of <50mls/min therefore PrEP cannot be 





Several trials demonstrated small decreases in bone mineral density (BMD) during the 
first 24 weeks of PrEP use which did not progress thereafter.  The risk of small BMD 
changes should be set against the benefit of PrEP in averting HIV infection with the need 
for lifelong ART. 
 
Treatment of HIV infection with single or dual agent NRTI therapy is associated with the 
rapid development of viral resistance.  There is therefore a risk of resistance if PrEP is 
commenced when there is undiagnosed HIV infection. It is essential to test for HIV prior 
to starting PrEP, and to be aware that some point of care antibody tests can remain 
negative for up to three months in acute HIV infection [45].  Repeat testing is therefore 
important soon after starting, and thereafter regular testing every 3 months, 
particularly in those who use PrEP intermittently.  
 
In trials, the risk of resistance was low but greater in those treated with active PrEP 
versus placebo. In a systematic review and meta-analysis of six trials reporting 
resistance data, of 44 participants subsequently found to have had HIV at enrolment, 8 
had TDF or FTC mutations of whom 6 had received active PrEP.  Just 6 of 533 
participants who acquired HIV post randomisation had TDF or FTC resistance of whom 
5 were randomised to active treatment [28**]. Two of three PROUD participants with 
HIV infection at enrolment or at their 4 week visit had the reverse transcriptase 
mutation M184V, probably selected through exposure to FTC [23]. In the absence of a 
reactive point of care antibody test or clinical suspicion of acute HIV infection, in 
individuals with on-going high risk of HIV infection it is nonetheless preferable to start 
PrEP promptly rather than to delay it over theoretical concerns about resistance [8**]. 
With larger scale implementation of PrEP, active surveillance for changes in resistance 
patterns will be essential.   
 
There is no known association between either TDF or TDF-FTC and adverse fetal or 
neonatal outcomes [42, 46].  Pregnant women are usually excluded from PrEP trials but 





Oral TDF and TDF-FTC are active against chronic hepatitis B infection, and there are 
concerns about the danger of hepatitis flares or liver injury if PrEP is discontinued [47].  
Chronic hepatitis B was an exclusion criterion in most PrEP trials therefore data are 
limited.  iPREX reported on 6 participants chronically infected with hepatitis B who 
received active PrEP;  5/6 had liver function tests 12 weeks after stopping treatment of 
whom one had a grade 1 elevation in transaminases [48].  Current guidance is to screen 
for active HBV infection in those starting PrEP [8**, 9, 10].  Daily PrEP is preferred over 
intermittent use. 
 
Although a systematic review found no evidence that PrEP led to changes in sexual 
behaviour [28**] these findings may not apply to those taking PrEP outside of a 
research setting.  The open-label nature of the PROUD trial, comparing PrEP with no 
PrEP, may provide a more realistic picture.  Whilst there was no significant difference in 
self-reported sexual behaviour, bacterial STIs were numerically more common in the 
immediate PrEP group although the difference was not statistically significant [23*].  
Further data is likely to emerge from open-label extensions of other studies and PrEP 
implementation studies. 
 
The future of PrEP: looking towards implementation 
 
Analyses covering varied settings and populations suggest that PrEP is cost-effective 
when set against the cost of long-term treatment and care for HIV [49, 50, 51]. However 
implementation in many countries is progressing slowly. Meanwhile some individuals 
are buying generic TDF-FTC, often from on-line suppliers. The quality and safety of 
drugs purchased in this way cannot be guaranteed, but voluntary groups and health 
services are helping to support patients with monitoring, and testing drug levels, to 
verify that the medication at least contains active drug. With limited programmes in 
place we are far from having equity of access.   
 
The cost effectiveness of PrEP increases with the risk of HIV infection in the population, 
therefore targeting treatment to those at highest risk is important. Risk will also vary 
over time; when risk falls the need for PrEP may cease. Reports from PrEP trials show 
that those who withdraw or are lost to follow-up may be at risk. Whilst trials do not 
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suggest that PrEP modifies sexual behaviour to the extent that the benefits are lost, it is 
essential that those taking PrEP have regular HIV and other STI testing. Wider 
availability of PrEP may also result in uptake amongst those at lower risk, and 
continued surveillance of trends in STI rates and sexual behaviour will be important. 
The high rates of STI and substance use in PrEP users reported recently [52] emphasize 
that PrEP should be part of a broader package of sexual health care and harm reduction.  
Yet the overwhelming evidence for the efficacy, safety, tolerability and acceptability of 
PrEP means that it should be included as a key component in the global effort to control 
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